Tirzepatide for Obesity Treatment and Diabetes Prevention

Тирзепатид для лечения ожирения и профилактики сахарного диабета
Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad, Sean Wharton, Shuyu Zhang, Mathijs C. Bunck, Adam Stefański, Carel Wynand le Roux, Leigh Perreault, John P.H. Wilding, Irina Jouravskaya, Bruno Halpern, Ramakrishna Battula, Mathijs C. M. Bunck
2024-11-13

SURMOUNT-1 trialobesity treatmentprediabetestirzepatidetype 2 diabetes prevention
BACKGROUND: Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here, we report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying progression to type 2 diabetes in persons with both obesity and prediabetes. METHODS: We performed a phase 3, double-blind, randomized, controlled trial in which 2539 participants with obesity, of whom 1032 also had prediabetes, were assigned in a 1:1:1:1 ratio to receive tirzepatide at a once-weekly dose of 5 mg, 10 mg, or 15 mg or placebo. The current analysis involved the participants with both obesity and prediabetes, who received their assigned dose of tirzepatide or placebo for a total of 176 weeks, followed by a 17-week off-treatment period. The three key secondary end points, which were controlled for type I error, were the percent change in body weight from baseline to week 176 and onset of type 2 diabetes during the 176-week and 193-week periods. RESULTS: At 176 weeks, the mean percent change in body weight among the participants who received tirzepatide was -12.3% with the 5-mg dose, -18.7% with the 10-mg dose, and -19.7% with the 15-mg dose, as compared with -1.3% among those who received placebo (P<0.001 for all comparisons with placebo). Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 to 0.1; P<0.001). After 17 weeks off treatment or placebo, 2.4% of the participants who received tirzepatide and 13.7% of those who received placebo had type 2 diabetes (hazard ratio, 0.12; 95% CI, 0.1 to 0.2; P<0.001). Other than coronavirus disease 2019, the most common adverse events were gastrointestinal, most of which were mild to moderate in severity and occurred primarily during the dose-escalation period in the first 20 weeks of the trial. No new safety signals were identified. CONCLUSIONS: Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo. (Funded by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
1
After 17 weeks without treatment, type 2 diabetes occurred in 2.4% of tirzepatide recipients versus 13.7% of placebo recipients (hazard ratio, 0.12).
2
Over 176 weeks, tirzepatide produced dose-dependent mean weight reductions of 12.3%, 18.7%, and 19.7% with 5-, 10-, and 15-mg doses, respectively, versus 1.3% with placebo.
3
The reported 3-year safety profile was characterized mainly by gastrointestinal adverse events, most of which were mild to moderate, aside from coronavirus disease 2019.
4
The trial evaluated 1032 participants with obesity and prediabetes in a phase 3, double-blind, randomized, placebo-controlled design with 176 weeks of treatment and a 17-week off-treatment follow-up.
5
Tirzepatide substantially reduced progression from prediabetes to type 2 diabetes: 1.3% versus 13.3% with placebo over 176 weeks (hazard ratio, 0.07).

Tirzepatide-treated adults with obesity and prediabetes

Long-term effects on body-weight reduction, type 2 diabetes progression, and safety over 176 weeks plus a 17-week off-treatment period

Publication Details
Publication Date
2024-11-13
Journal
Publisher
ISSN
Cited by
530
Access Type
Author Information
Authors
Ania M. Jastreboff
Louis J. Aronne
Nadia N. Ahmad
Sean Wharton
Shuyu Zhang
Mathijs C. Bunck
Adam Stefański
Carel Wynand le Roux
Leigh Perreault
John P.H. Wilding
Irina Jouravskaya
Bruno Halpern
Ramakrishna Battula
Mathijs C. M. Bunck
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%